Latest News and Press Releases

LONDON, Aug. 15, 2006 (PRIMEZONE) -- Cancer drug developer Antisoma plc (LSE:ASM) (Pink Sheets:AIOAF) today provides an update on its commercialisation strategy for AS1404 and progress in the drug's...

LONDON and PHILADELPHIA, Nov. 16, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma plc (LSE:ASM) announces the presentation of long-term follow-up data from the phase I trial of its aptamer drug...

LONDON and PHILADELPHIA, Nov. 15, 2005 (PRIMEZONE) -- A presentation today at the AACR-NCI-EORTC meeting in Philadelphia offers new insights into the mechanism of action of Antisoma's phase II cancer...

LONDON, Nov. 2, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma plc (LSE:ASM) today announces that it will be presenting at the upcoming SG Cowen and Rodman & Renshaw healthcare conferences....

LONDON and PARIS, Nov. 1, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma (LSE:ASM) will today present data on its most advanced drug, AS1404, at ECCO -- the European Cancer Conference. AS1404...

LONDON, Oct. 17, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma (LSE:ASM) today announces preliminary findings from an ongoing phase II trial of AS1404 in lung cancer. With initial data...

LONDON, Sept. 15, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma plc (LSE:ASM) today announces its preliminary results for the year ended 30 June 2005. Highlights of 2004/2005 Advances...

LONDON, Sept. 6, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma (LSE:ASM) announces that it has reopened a U.S. phase I trial of its aptamer drug AS1411 following the presentation of promising...

LONDON, Sept. 1, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma (LSE:ASM) announces that it has reached the patient recruitment target in its phase II trial of AS1404 in non-small cell lung...

LONDON, Aug. 17, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma (LSE:ASM) has received notification from the U.S. Food and Drug Administration (FDA) that its aptamer drug AS1411 has been granted...